WEIZMANN INSTITUTE OF SCIENCE

Their core work

The Weizmann Institute of Science is one of the world's leading multidisciplinary research institutions, headquartered in Rehovot, Israel. Their H2020 portfolio reveals deep strengths in fundamental life sciences — neuroscience, cancer biology, immunology, and genomics — alongside significant work in computational biology, structural biology, and mathematical sciences. They are a major engine for translating basic scientific discoveries toward biomedical and technological applications, with a strong track record in ERC-funded investigator-driven research. Their work spans from understanding brain circuits and the microbiome to developing personalized cancer therapies and advanced imaging technologies.

What they specialise in

How they've shifted over time

In the early H2020 period (2014–2018), Weizmann's focus centered on neuroscience (hippocampus, place cells, brain simulation, neuroinformatics), structural biology, and computational infrastructure — reflecting their strength in fundamental brain research and bioinformatics. By the later period (2019–2022), a pronounced shift toward cancer biology, immunotherapy, microbiome science, and chemical biology is visible, with cancer appearing as the single most frequent keyword. This evolution signals a move from basic neuroscience and computational work toward translational biomedical research with clearer clinical and therapeutic relevance.

Weizmann is increasingly investing in translational cancer research, immunotherapy, and microbiome science — making them a strong future partner for projects bridging fundamental biology with clinical applications.

How they like to work

Weizmann overwhelmingly leads its projects: 142 of 214 H2020 projects are coordinated by the institute, driven by the high share of individual ERC grants (101 ERC projects across Starting, Consolidator, Advanced, and Proof of Concept). When participating in collaborative projects, they typically serve as a specialized scientific partner contributing deep expertise rather than managing large consortia. With 609 unique partners across 40 countries, they maintain a broad but research-community-centered network — expect to work with world-class principal investigators who value scientific independence.

Weizmann has collaborated with 609 distinct partners across 40 countries, indicating a truly global research network despite Israel's geographic position outside the EU core. Their partnerships span major European research universities and infrastructure networks, with particularly strong connections through large-scale initiatives like the Human Brain Project and ELIXIR.

What sets them apart

Weizmann stands out as one of the most ERC-intensive institutions in H2020 — with over 100 ERC grants, their portfolio is dominated by investigator-driven frontier research at the highest level. Unlike many universities that participate broadly across EU programmes, Weizmann's strength is concentrated in attracting top individual talent funded through competitive excellence schemes. For consortium builders, partnering with Weizmann means access to world-class principal investigators in life sciences, a rarity among non-EU-member institutions with this depth of European funding integration.

Highlights from their portfolio

• LineageDiscovery
  EUR 2.25M ERC Advanced Grant to map human cell lineage — one of Weizmann's largest single awards, combining biology with computational architecture.
• NeurogenesisCode
  EUR 1.5M ERC grant deciphering how adult-born neurons contribute to hippocampal memory, exemplifying their deep neuroscience pedigree.
• COMbAT
  ERC Proof of Concept grant commercializing a personalized melanoma therapy tool — illustrates Weizmann's push from bench science toward translational impact.